Supreme Court Keeps Abortion Pill Access in Place

Estimated Time to Read: 8 minutes

The U.S. Supreme Court issued a consequential emergency order last Thursday that temporarily blocked a Fifth Circuit ruling out of Louisiana, which would have reinstated restrictions on the mailing of Mifepristone, the abortion-inducing drug commonly used in chemical abortions.

The order leaves current Food and Drug Administration (FDA) rules in place while litigation continues in the lower courts, meaning mifepristone may continue to be prescribed remotely and shipped through the mail nationwide for now. Although the ruling was procedural rather than final, it represents another major turning point in the post-Dobbs legal battle over abortion policy, federal authority, and interstate enforcement.

The Supreme Court’s action also arrives just months after Texas lawmakers passed House Bill 7 (HB 7) during the Second Called Session of the 89th Texas Legislature (2025), legislation specifically designed to prohibit the manufacture, distribution, mailing, transportation, delivery, and provision of abortion-inducing drugs in Texas through a private civil enforcement structure modeled after Senate Bill 8 (SB 8), passed in the 87th session (2021), also known as the Texas Heartbeat Act.

Taken together, the federal litigation and Texas’s newly enacted law illustrate how the next phase of the abortion debate is increasingly centered not only on abortion itself, but also on telemedicine, pharmaceutical regulation, state sovereignty, interstate commerce, and the limits of federal administrative power.

Supreme Court Blocks Fifth Circuit Order on Mifepristone Access

The dispute stems from Louisiana v. FDA, where Louisiana challenged FDA rules that loosened restrictions on mifepristone distribution over the last several years. Among the most significant changes were the removal of in-person dispensing requirements and the expansion of telehealth prescribing and mail delivery.

Earlier this month, the Fifth Circuit temporarily reinstated portions of the older regulatory framework, effectively requiring in-person dispensing while litigation continued. That ruling would have sharply restricted the ability of abortion providers and pharmacies to distribute the drug remotely. Drug manufacturers Danco Laboratories and GenBioPro quickly appealed to the Supreme Court, arguing that the Fifth Circuit’s order would create nationwide disruption and interfere with a federally approved pharmaceutical distribution system that has operated for years.

The Supreme Court ultimately granted emergency relief and blocked the Fifth Circuit order from taking effect. The Court issued the order without a full opinion, preserving the current status quo while lower court proceedings continue.

As a practical matter, telehealth prescribing and mail distribution of mifepristone remain legal under current federal rules while the litigation moves forward.

Justices Thomas and Alito Signal Bigger Battles Ahead

Although the Court’s majority issued no explanation, Justices Clarence Thomas and Samuel Alito publicly dissented.

Their dissents are significant because they preview several legal theories that could eventually reshape abortion pill regulation nationwide.

Thomas questioned whether the drug manufacturers were entitled to emergency relief and raised concerns regarding the continuing applicability of federal mailing laws, particularly the Comstock Act of 1873. Alito similarly argued that the Court’s intervention may improperly interfere with states seeking to enforce abortion restrictions after Dobbs returned abortion policymaking authority to the states.

The dissents suggest that at least two members of the Court are open to broader arguments concerning whether federal law already prohibits mailing abortion-inducing drugs regardless of FDA policy.

That issue could become one of the defining legal questions of the next several years.

The Comstock Act Returns to the Spotlight

Much of the renewed legal focus centers around the Comstock Act, a 1873 federal law prohibiting the mailing of materials intended for abortion.

For decades, the statute was rarely enforced in modern abortion litigation. However, abortion opponents increasingly argue that the law remains operative and prohibits the interstate shipment of abortion-inducing drugs. Supporters of current FDA policy counter that the agency possesses broad federal authority to regulate pharmaceutical safety and distribution and that the statute has long been interpreted more narrowly in modern practice.

The Supreme Court did not resolve that issue in its recent order. However, the Thomas and Alito dissents strongly indicate the question remains active within the Court. That matters because if courts ultimately interpret the Comstock Act broadly, the implications could extend well beyond Louisiana’s challenge and potentially affect abortion pill distribution nationwide.

Texas House Bill 7 Was Designed for This Legal Environment

The Supreme Court’s order also directly intersects with Texas’ recent legislative actions.

During the Second Called Session of the 89th Legislature, lawmakers passed House Bill 7, known as the Woman and Child Protection Act. The law prohibits the manufacture, distribution, mailing, transportation, delivery, prescribing, or provision of abortion-inducing drugs in Texas except in limited circumstances.

Unlike traditional criminal enforcement mechanisms, HB 7 relies almost exclusively on private civil enforcement through qui tam actions. The legislation specifically bars direct state enforcement and instead allows private individuals to bring lawsuits against those alleged to have violated the law.

Texas Policy Research (TPR) previously noted that the legislation was designed not only to prohibit abortion-inducing drugs within Texas, but also to respond to the increasingly interstate nature of abortion pill distribution following Dobbs. The bill further attempts to insulate Texas residents and courts from out-of-state “shield laws” and “clawback provisions” adopted by abortion-friendly states. It also grants broad jurisdictional authority to Texas courts and provides for substantial statutory damages of at least $100,000 per violation.

In many ways, HB 7 reflects the broader post-Dobbs legal strategy now emerging nationally. Rather than focusing solely on direct abortion bans, states are increasingly targeting the infrastructure surrounding abortion access, including telemedicine, pharmaceutical shipping, digital facilitation, and interstate regulatory conflicts.

Texas Right to Life President John Seago argued that the Supreme Court’s order should not be viewed as the final word on the issue, saying, “We shouldn’t have to depend on the court to force the FDA to do the right thing. The administration could choose to restore the in-person requirement themselves right now. Safeguards like these are the bare minimum. Washington should be doing more to protect all babies and their mothers from the violence of abortion.”

Seago’s comments reflect a broader strategic shift among abortion opponents following Dobbs. Rather than focusing exclusively on state-level abortion bans, many organizations are increasingly targeting the federal regulatory framework surrounding abortion-inducing drugs, including telehealth prescribing practices, interstate shipping, and FDA enforcement policies.

State Sovereignty and Federal Authority Are Increasingly Colliding

One of the largest unresolved questions in the litigation is whether federal FDA authority preempts state abortion restrictions.

Louisiana and other states argue that they retain sovereign authority to prohibit abortion-inducing drugs within their borders even if the FDA has approved those drugs for distribution nationally.

Opponents of Louisiana’s position argue that allowing states to override FDA distribution rules could create a fragmented pharmaceutical system where federally approved medications become effectively subject to fifty different regulatory regimes.

The Supreme Court’s order does not resolve that conflict, but it places the issue squarely at the forefront of future litigation.

For Texas, the question is particularly important because HB 7 was carefully drafted to maximize state authority while attempting to avoid direct federal preemption conflicts. The legislation expressly acknowledges potential federal preemption limitations while still asserting broad state jurisdiction.

This tension between state sovereignty and federal administrative authority will likely become one of the defining constitutional battles of the post-Dobbs era.

Telehealth Rules Could Change

The implications of the case extend well beyond abortion policy.

Since the COVID-19 pandemic, federal regulators have significantly expanded telehealth prescribing and remote pharmaceutical distribution practices across multiple sectors of health care.

A ruling restricting the mailing of Mifepristone could invite broader scrutiny of emergency-era regulatory expansions and raise questions about the extent of agency authority to bypass traditional in-person medical requirements. Likewise, a ruling favoring broad state authority could embolden states to impose additional restrictions on federally regulated products in other politically contentious policy areas.

At the same time, a ruling broadly affirming federal supremacy over pharmaceutical regulation could significantly constrain state efforts to regulate abortion-inducing drugs independently. The case, therefore, represents not only an abortion dispute but also a broader debate over administrative law, interstate commerce, and the future structure of federalism in health care regulation.

The Supreme Court Likely Has Not Heard the Last of This Case

The Court’s recent order is temporary and procedural. The litigation now returns to the lower courts, where additional proceedings regarding standing, federal preemption, FDA authority, and the Comstock Act will continue.

Earlier this year, portions of the case were paused while the Trump administration conducts an FDA review of mifepristone safety and distribution policies. However, the Fifth Circuit’s intervention and the Supreme Court’s emergency order demonstrate that the courts remain deeply engaged in the dispute.

Legal observers widely expect the case to return to the Supreme Court after additional lower court proceedings. That eventual decision could reshape not only abortion pill access, but also the balance of power between federal agencies and the states.

The Legal Battle Is Far From Over

For now, the Supreme Court has preserved existing access to mail-order mifepristone while the litigation proceeds, but the Court’s order did not settle the underlying legal questions. Instead, it highlighted just how unsettled those questions remain. The dissents from Thomas and Alito suggest that major constitutional and statutory disputes regarding abortion-inducing drugs, federal mailing laws, and state sovereignty are still very much alive within the federal judiciary.

Meanwhile, states like Texas continue constructing increasingly sophisticated legal frameworks aimed at restricting abortion pill access through private enforcement mechanisms, jurisdictional protections, and interstate litigation strategies.

The result is a rapidly evolving legal landscape where abortion policy is no longer defined solely by direct bans, but by overlapping conflicts involving federal agencies, interstate commerce, telehealth regulation, and constitutional federalism.

And based on the Supreme Court’s recent order, those conflicts are only beginning.

---